We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

13 hedge funds and large institutions have $3.66M invested in Seelos Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

19% more capital invested

Capital invested by funds: $3.07M → $3.66M (+$587K)

35% less funds holding

Funds holding: 20 → 13 (-7)

88% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 8

Holders
13
Holders Change
-7
Holders Change %
-35%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
2
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$107K
2
BlackRock
BlackRock
New York
+$88.2K
3
MWP
MYCIO Wealth Partners
Pennsylvania
+$7.67K
4
UIC
Uniplan Investment Counsel
Wisconsin
+$7.67K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$451K
2
WS
Wedbush Securities
California
-$75K
3
VF
Virtu Financial
New York
-$68K
4
ARTA
A.R.T. Advisors
New York
-$63K
5
CH
CVI Holdings
Delaware
-$54K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$1.5M +$107K +28 +11%
UIC
2
Uniplan Investment Counsel
Wisconsin
$890K +$7.67K +2 +1%
BlackRock
3
BlackRock
New York
$541K +$88.2K +23 +28%
Vanguard Group
4
Vanguard Group
Pennsylvania
$321K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$206K – – –
AAP
6
Ardsley Advisory Partners
Connecticut
$67K – – –
MWP
7
MYCIO Wealth Partners
Pennsylvania
$41K +$7.67K +2 +33%
Squarepoint
8
Squarepoint
New York
$28K – – –
Northern Trust
9
Northern Trust
Illinois
$26K -$7.67K -2 -29%
TSS
10
Two Sigma Securities
New York
$18K -$7.67K -2 -33%
WP
11
WealthPLAN Partners
Nebraska
$16K – – –
LTFS
12
Ladenburg Thalmann Financial Services
Florida
$3K – – –
PA
13
Procyon Advisors
Connecticut
$3K +$3.83K +1 New
PAM
14
Panagora Asset Management
Massachusetts
$2K – – –
SM
15
Sabby Management
Florida
– -$451K -128 Closed
WS
16
Wedbush Securities
California
– -$75K -21 Closed
VF
17
Virtu Financial
New York
– -$68K -19 Closed
ARTA
18
A.R.T. Advisors
New York
– -$63K -18 Closed
CH
19
CVI Holdings
Delaware
– -$54K -15 Closed
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
– -$17K -5 Closed
NFG
21
Nadler Financial Group
Illinois
– -$12K -3 Closed
Victory Capital Management
22
Victory Capital Management
Texas
– -$3K -1 Closed

SEEL Hedge Fund Activity: Q4 2019 in Review

13 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2019, worth a combined $3.66M — up 19% from $3.07M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of SEEL and 1 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was Renaissance Technologies, adding an estimated $107K. The largest seller was Sabby Management, exiting entirely with an estimated $451K sold.

  • 13 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2019, down from 20 in Q3 2019.
  • Funds reported $3.66M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2019, up 19% quarter-over-quarter.
  • 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2019 and 8 closed out, a net change of -7 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $107K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2019 was Sabby Management, an estimated $451K sold.

Based on aggregated 13F filings for Q4 2019.